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FOXP3 is a multifaceted transcription factor with a major role in the control of immune
homeostasis mediated by T regulatory cells (Treg). The immunoregulatory function of
FOXP3 may hinder the induction of immune responses against cancer and infectious
agents, and thus, development of inhibitors of its functions might give new therapeu-
tic opportunities for these diseases. But also, FOXP3 is an important tumor suppressor
factor in some types of cancers, and therefore, understanding the structure and function
of FOXP3 is crucial to gaining insights into the development of FOXP3-targeted therapeutic
strategies. FOXP3 homodimerize and likely form supramolecular complexes which might
include hundreds of proteins which constitute the FOXP3 interactome. Many of the func-
tions of FOXP3 are clearly regulated by the interactions with these cofactors contributing
importantly on the establishment of Treg-cell signature. We summarize here the struc-
tural/functional information on this FOXP3 complex, to identify potential opportunities for
the development of new strategies to modulate FOXP3 activity.
Keywords: foxp3, FOXP3 interactome,Treg, drug discovery, immunosuppression
FOXP3, A MEMBER OF FOX FAMILY, WITH
IMMUNOREGULATORY PROPERTIES
Forkhead (FKH) proteins are a very large family of transcrip-
tion factors implicated in a variety of cellular processes (1). They
are characterized by the presence of a highly conserved 100-
amino-acid FKH-binding domain (FKH). The crystal structure
of the FKH domain bound to DNA has been solved and has been
described as a“winged-helix”similar to the shape of a butterfly (2).
In the last years, more than 100 members, classified in 15 sub-
families of FOX proteins, have been identified (3). They are com-
monly associated with the regulation of development. Whereas
the FKH domain defines this class of transcription factors, other
portions of the Fox proteins, which encode for instance trans-
activation or trans-repression domains, are highly divergent and
little is known about their interactions with the transcriptional
machinery.
FOX gene mutations have been found to be responsible
for diverse phenotypes, from craniopharyngeal development
(FOXE1), hair development (Foxq1 and Foxn1) to speech and
language development (FOXP2) and hearing (Foxi1) (4). In the
last years, it has become clear that these winged-helix proteins
have crucial roles in various aspects of immune regulation. Thus,
the scurfy mutant mouse strain, which suffers from a fatal lym-
phoproliferative disease leading to early death within 3–4 weeks
of age, presents a frame-shift mutation of the FKH box transcrip-
tion factor Foxp3 responsible of this disease (5). This affection
is characterized by splenomegaly, insulitis, hepatomegaly, lym-
phadenopathy, and massive lymphocytic infiltrates in the skin and
liver, suggesting that mutation in FOXP3 leads to an autoimmune
disease.
In humans, mutations in FOXP3 results in an autoimmune syn-
drome termed IPEX (immunodysregulation, polyendocrinopa-
thy enteropathy, X-linked syndrome), an X-linked immunode-
ficiency syndrome characterized by insulin-dependent diabetes,
thyroiditis, massive T-cell infiltration in multiple organs and
chronic wasting (6–8).
Analysis of FOXP3 expression revealed that it was most highly
expressed in lymphoid organs, such as the thymus and spleen,
and more specifically by CD4+ T cells. The relevance of Foxp3
expression in CD4+ T cells was evidenced when it was found that
adoptive transfer of wild-type CD4+CD8− lymphocytes could
control the T cells of scurfy mice, thereby preventing the devel-
opment of disease (9). This observation suggested that CD4+ T
cells expressing the wild-type Foxp3 gene played a regulatory role
being able to suppress the activity of other immune cells. This
was confirmed when CD4+CD25+ T cells were identified as cells
able of suppressing proliferation and cytokine production of TCR-
stimulated conventional CD4+ T cells (10, 11). Foxp3 expression
in CD4+ T cells was found to be sufficient to mark these cells
as regulatory (Treg cells). Indeed, infection of CD4+CD25− T
cells with a retrovirus expressing Foxp3, converted them to a reg-
ulatory phenotype, able to suppress proliferation of conventional
CD4+ CD25− T cells (12) and protect mice from autoimmune
gastritis. These studies demonstrated that CD4+CD25+ T regu-
latory cells with a major role in the suppression of autoreactive T
cells, and preventing autoimmunity. The activity of Foxp3 was also
confirmed in transgenic mice overexpressing Foxp3 (13), and curi-
ously, it was found that also CD8+ T cells overexpressing Foxp3
displayed in vitro regulatory activity, showing that Foxp3 expres-
sion on non-CD4 T cells was also capable to re-program the cell
phenotype.
FOXP3 AND CANCER
Treg cells inhibit activation of other T cells and are needed for
protection against autoimmune diseases. However, immunoreg-
ulatory function of Treg may hinder the induction of immune
responses against cancer and infectious agents (14–20). Indeed,
Treg capable of suppressing the in vitro function of tumor-reactive
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T cells have been found in humans in many types of tumors (16–18,
20) and have been associated with a high death hazard and reduced
survival (16–18). However, there are discrepancies in the prognos-
tic studies relying on the presence of Treg in tumor infiltrates, and
paradoxically, a high density of FOXP3+ T-cell infiltration was
associated with improved overall survival in patients with colorec-
tal, head and neck carcinoma, or patients with lymphoma (21–23).
It has been postulated that Treg could in these cases modulate
the tumor microenvironment and influence the biologic behavior
of tumoral cells. A better understanding of the biologic role of
FOXP3-positive Tregs in these tumors is needed.
Despite a clear role in Tregs, FOXP3 protein expression is not
restricted to the lymphocyte lineage but is also present in nor-
mal and cancer cells of non-hematopoietic origin (24–28). The
function of FOXP3 in cancer is somehow contradictory. Regard-
ing the expression of FOXP3 in human cancer cells and in their
normal homologs, two opposite situations have been found. It has
been described that in pancreatic cancers or in melanoma, FOXP3
expression is restricted to the tumor cells (24, 25). In contrast,
FOXP3 appears to be expressed in normal epithelial cells of human
breast and prostate, but downregulated in the corresponding can-
cer cells (29, 30). These data suggest a dual role of FOXP3, one
linked to immune escape and another to tumor suppression (31).
On the one hand, it has been shown that FOXP3 expression
in melanoma cells (26) or in pancreatic carcinoma cells (25) ren-
ders the tumor cells suppressive with Treg-like activity to directly
inhibit the proliferation of T cells and suggesting a possible mech-
anism of tumor resistance to immune system. However, on the
other hand, several works have demonstrated that the expression
of FOXP3, especially in breast cancer cells, is an X-linked can-
cer suppressor gene and an important regulator of the epidermal
growth factor receptor (HER2/ErbB2) and SKP2 oncogenes (27,
30). The expression of Foxp3 has been evidenced in a significant
number of cancer types, although its role in tumor progression
remains to be elucidated (32).
THE INTERACTOME OF FOXP3
FOXP3 is essential for the specification and maintenance of Treg
cells, and thus, it was considered as the “master regulator” of
Treg cells although it was described that cells with many of the
Treg-cell characteristics, can differentiate at least transiently, in the
absence of FOXP3 (33,34). The molecular basis of FOXP3 function
has been poorly understood. As described above, genome-wide
analyses of Foxp3 targets has revealed that FOXP3 induces both
activation and repression of its target genes (33–37). The capacity
of FOXP3 to bind DNA is critical for its functionality; however, it is
clear that FOXP3-DNA interactions are assisted by FOXP3 cofac-
tors and by multimerization. After a careful meta-analysis that
combined gene-expression profiles, generated in several parallel
experiments, Hill et al. identified 603 target genes (407 over-
expressed and 196 underexpressed) that compose the canonical
Treg-cell signature (38). Importantly, it was found that much of
the Treg-cell signature was not ascribable to Foxp3 because it
contained gene clusters that are co-regulated with, but not trans-
activated by FOXP3. Recently, Samstein et al. (39) examined chro-
matin accessibility of FOXP3-bound enhancers in Treg cells and
Foxp3- CD4+ T cells. They showed that FOXP3 was bound mainly
to enhancers already accessible in precursor CD4+ FOXP3- T cells,
with only a small subset of exclusively Treg-restricted enhancers
found in several genes important for Treg-cell function. Analysis
of DNA sequences at FOXP3-binding sites identified a FKH motif
only in a small subset of these DNA regions (39), suggesting the
contribution of other cofactors on the establishment of Treg-cell
signature.
Indeed, it has been described that FOXP3 homodimerize and
likely form supramolecular complexes (40). Growing numbers of
transcription factors that interact with FOXP3 are being identified
and some have been implicated in the Treg-cell-specific gene-
expression program (37, 40, 41). In a recent paper, a chromato-
graphic analyses of nuclear lysates revealed that FOXP3 protein
was present in large 400–2,000 kDa complexes (41). In this work,
Rudra et al. identified 361 partners of FOXP3 by using a pro-
teomic approach. They found that these partners were implicated
in several biological processes such as DNA binding, transcription
regulator activity, chromatin binding, regulation of transcrip-
tion, chromosome organization, chromatin modification as well
as RNA binding, processing, splicing, and metabolism suggest-
ing a yet unexplored RNA-associated role of FOXP3. Recently, Fu
et al. by using computational network inference, confirmed that
FOXP3 expression was responsible of around 10% of the whole
Treg signature and identified five transcription factors (Eos, IRF4,
Satb1, Lef1, and GATA-1), which they named “the quintet” that
interact with and act together with FOXP3 to elicit much of the
characteristic Treg-cell transcriptional signature (37).
This observation is consistent with the fact that the majority
of FOXP3-binding sites in the genome lack an identifiable FKH-
binding motif in Treg cells and suggests that FOXP3 cofactors
may facilitate binding of FOXP3 to a given site either through
direct recruitment of FOXP3-containing complexes or through
facilitating interactions with FOXP3-bound sites containing FKH
motif via loop formation (35, 36, 39). It is clear that FOXP3 func-
tions, and consequently the phenotype of the FOXP3-expressing
cell may change depending on the partners forming the FOXP3
interactome, which might in addition, depend on the activation
status of the cell.
A significant number of FOXP3-interacting proteins have been
identified, including TIP60,HDAC7,HDAC9,Eos, Irf4, and Hif-1α
(40, 42–48). The proteomic analysis of FOXP3-complexes con-
ducted by Rudra et al., found that the majority of FOXP3 partners
consisted of proteins that have been implicated in regulation
of transcription including many sequence-specific transcription
factors such as NFATc2, Runx1, Bcl11b, Foxp1, Foxp4, GATA-3,
STAT3, Ikaros (Ikzf1), Aiolos (Ikzf3), Ets, and Cnot3. It has been
postulated that the differentiated state of Treg cells is not deter-
mined by individual regulatory components, but instead by the
collective activity of their transcriptional network (37, 41, 49).
This hypothesis has important implications on the functionality
of Tregs, and raises new possibilities for the design of new ther-
apies where Treg cells or FOXP3 expression and function have
pathological consequences. Indeed, those strategies able to inhibit
a particular interaction with FOXP3, or able to modify the FOXP3
interactome might have important consequences on the whole
transcriptome signature of the FOXP3-expressing cell and con-
sequently, on its activity. Thus, a structure/function analysis of
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FOXP3 might help on the understanding of the rules governing
the formation of such interactome.
THE STRUCTURE/FUNCTION ANALYSIS OF FOXP3
The FOXP3 gene is located on the X chromosome and contains 11
coding exons (exons 1–11) and 3 non-coding exons (5). FOXP3
has various distinguishable functional domains: (i) an N-terminal
domain (from a.a. 1 to 193, with two proline-rich regions) respon-
sible for transcriptional repression, (ii) a zinc finger (a.a. 200–223)
and a leucine-zipper (LZ)-like motif (a.a. 240–261) (ZL domain)
located in the center of the protein, which facilitates the formation
of FOXP3 homo-dimers or tetramers, and (iii) the highly con-
served carboxy terminal FKH domain (FKH; from a.a. 338 to 421)
responsible for the DNA binding. The analysis of FOXP3 variants
containing mutations found in IPEX patients have offered some
evidences about the function of these domains. Mutations have
been found throughout FOXP3 indicating that these regions of the
protein are important for proper function (50, 51). Identification
of the functional consequences of these individual mutations is
critical to gain insights into possible treatments for Foxp3-related
pathologies.
THE AMINO TERMINAL REGION OF FOXP3
The N-terminal of FOXP3 has been involved in the interaction
with several transcription factors, which are related to the suppres-
sive transcriptional activity of FOXP3. Lopes et al. evaluated the
location of point mutations identified in a large cohort of patients
with the IPEX syndrome, and found them to cluster primarily in
the FKH domain and the leucine zipper, but also in the N-terminal
portion of the protein (51). They identified a functional domain
in this N-terminal region of FOXP3 which is required for FOXP3-
mediated repression of transcription. They mapped the functional
repressor domain between aminoacids 67 and 132.
One of the key features of Treg cells is to maintain the aner-
gic status in response to stimulation. In this regard, Lee et al.
found that the N-terminus of FOXP3 specifically interacts with
and alters subnuclear localization of phosphorylated c-Jun (52),
a member of the AP-1 transcription factors which participates
in the control of cell proliferation, differentiation, cell death, and
cell transformation in response to stimuli (53). This interaction
inhibits the promoter DNA-binding activity of c-Jun and induces
T-cell anergy.
As mentioned above, FOXP3 expression is not restricted to the
lymphocyte lineage but it is also present in cancer cells, especially
in breast cancer cells, where it has been demonstrated to be a cancer
suppressor gene and an important regulator of the HER2/ErbB2
and SKP2 oncogenes (27, 30). It has been described that this tumor
suppressor activity is located in the N-terminal region of Foxp3,
since a C-truncated versions of the protein do not retain this prop-
erty (54). The authors described that this activity was independent
of NFAT-FOXP3 interaction which is located in the FKH region of
FOXP3 (55). It is tempting to postulate that the tumor suppressor
activity of Foxp3 is mediated by its capacity to alter the activation
of AP-1 through its interaction with c-Jun.
The suppression of CD4+ T cells proliferation is also main-
tained through the interaction of Foxp3 N-terminal domain with
Eos, a zinc-finger transcription factor of the Ikaros family (45).
Foxp3, Eos, and the C-terminal binding protein-1 (CtBP1), form
an inhibitory complex that suppresses the expression of genes.
Disruption of the interaction of Foxp3 and Eos leads to the fail-
ure of Treg to inhibit proliferation of T effector cells. The proline
rich N-terminal region of FOXP3 seems to be the responsible for
this interaction. However, this region alone is not sufficient to
confer Treg cells suppressive function, and NFAT-FOXP3 inter-
action through the FKH domain is also required (46, 52, 55). In
a recent paper, a new human-specific FOXP3-interacting protein
which couples FOXP3 to a chromatin-remodeling complex has
been identified to contact with this region (aa 106–198) (56).
The authors show that FIK protein (FOXP3-interacting KRAB
domain containing protein), acts as a bridging molecule to link
FOXP3 with the chromatin-remodeling scaffold protein KAP1
(TIF-1β/TRIM28) and that disruption of this complex restores the
expression of genes inhibited by FOXP3, and the suppressor activ-
ity of Tregs. Interestingly, expression of genes that were shown
to be positively regulated by FOXP3 (such as CTLA4 or CD25)
was not affected, suggesting that they were regulated by a different
mechanism.
In humans, there are two FOXP3 isoforms expressed in Treg
cells that lacks exon 2 (57), located in the N-terminal region of
FOXP3. It has been described that exon 2 is implicated in the
interaction with RORα and RORγt, transcriptional factors that
activate the expression of IL-17 and IL-22, which are related with
Th17 differentiation. RORγt binds to IL-17A promoter and the
interaction of Foxp3 with RORγt through exon 2 region of Foxp3
is able to suppress of RORγt-mediated IL-17A promoter activa-
tion. These results highlight the importance of Foxp3 N-terminal
domain in balancing the differentiation between Treg cells and
Th17 (58, 59).
The N-terminal of FOXP3 is also reported to interact with c-Rel
(60, 61), a member of the NF-κB family that is responsible for the
up-regulation of a variety of pro-inflammatory cytokines such as
IL-6, IL-12, IL-15, IFN-γ, or IL-2 (62, 63). Deletion of exon 1 was
sufficient to almost entirely abrogate c-Rel binding, although other
regions of FOXP3, such as exon 6 or exon 8 also abolished bind-
ing, suggesting that dimerization of Foxp3 or the interaction with
other proteins is required. The interaction between Foxp3 and c-
Rel may also contribute to the nuclear translocation of FOXP3.
Indeed, it has been shown that FKH-deleted FOXP3, which is
mainly located at cytoplasm, was predominantly found in the
nucleus in the presence of ectopically expressed c-Rel (60, 61).
In addition to the interaction with a number of transcrip-
tional factors, FOXP3 also interacts with enzymes that regulate the
activity of FOXP3 at post-translational level [reviewed in (64)].
Among these enzymes, histone acetyltransferase (HAT) TIP60
and histone deacetylase HDAC7 interact with the N-terminal of
FOXP3 and increase its suppressive transcriptional activity (43).
TIP60 promotes the acetylation of FOXP3, which enhances the
suppressive transcriptional activity of FOXP3, but TIP60 may
also play a role in regulating FOXP3 activity independent of its
HAT activity. The N-terminal 106–190 aa of FOXP3 are required
for TIP60-FOXP3, HDAC7-FOXP3 association, as well as for the
transcriptional repression of FOXP3 via its FKH domain (43).
Binding of TIP60 with FOXP3 may regulate the oligomerization
status of FOXP3 and therefore its DNA binding. Moreover, TIP60
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may also recruit additional factors required for transcriptional
repression/activation. A clear understanding of the involvement
of HDACs in the FOXP3 complex assembly will lead to insights
to develop new strategies to modulate Treg functions for human
disease (64).
Several of these interactions have been linked to a particu-
lar Treg-cell transcriptional profile. This is the case for IRF4 or
STAT3, which can affect, alone or in combination with FOXP3,
some segments of the Treg-cell signature (47, 65). Their pres-
ence should modulate the range of Treg effector functions. In
this way, it has been reported that a modification of the N-
terminus of Foxp3, results in diametrically opposite effects in the
severity of different autoimmune diseases. Mice expressing the
GFP-Foxp3 fusion protein modified Foxp3 molecular interactions,
blocking HIF-1α but increasing IRF4 interactions and resulted
in a divergent susceptibility to autoimmune disease: protection
against antibody-mediated arthritis, but greater susceptibility to
diabetes (66). Thus, specific subfunctions of Treg cells and the
immune diseases they regulate can be influenced by Foxp3’s molec-
ular interactions with particular partners, which result in different
patterns of immunoregulation.
ZINC FINGER AND LEUCINE ZIPPER
Dimerization of FOXP3 is required for its function as a transcrip-
tional regulator and the LZ of FOXP3 is necessary and sufficient
for this association (40, 51, 64, 67). In addition, the LZ of FOXP3
is implicated in the hetero-association with FOXP1 (64, 68). The
disease-associated mutations of the LZ domain disrupting FOXP3
dimerization can substantially reduce the binding of FOXP3 to
promoter regions in vivo (40, 51, 64, 67). These findings indi-
cate that the FOXP3 protein ensemble, as well as its DNA-binding
properties, could be modulated through oligomerization of the LZ
region. Song et al. have characterized the structure of the FOXP3-
Zinc finger and LZ (FOXP3-ZL) domain and identified two lysine
residues in the LZ region (K250 and K252) as key residues for the
conformational change and stability of the FOXP3 dimer. Acety-
lation of these K residues would neutralize the positive charges at
these sites through which the FOXP3 dimer stability is modulated
and result in changes in promoter occupancy, histone acetyla-
tion patterns, IL-2 gene-expression levels, and Treg suppression
activity.
Moreover, the LZ is also important for the interaction between
histone H1.5 and FOXP3, which cooperatively repress IL-2 tran-
scription in human T cells. This interaction alters histone H1.5
binding to target genes (i.e., IL-2 or CTLA4) to modulate their
expression and to program Treg function (69). Also, FOXP1-
FOXP3 hetero-associations through the LZ domain may compete
with FOXP3 homo-dimerization and the dynamic balance of dis-
crete forms of FOXP3-complexes may directly affect its repressor
activity (69).
FOXP3 interacts physically with the transcription factor
AML1 (acute myeloid leukemia 1)/Runx1 (Runt-related tran-
scription factor 1) (44), which is crucially required for normal
hematopoiesis including thymic T-cell development. Ono et al.
showed that this interaction suppresses IL-2 and IFN-γ pro-
duction, upregulates Treg-associated molecules, controls anergy
of the cell and exerts suppressive activity. They also found that
the AML1-interacting domain of the Foxp3 protein was located
between the FKH domain and the LZ motif (amino acids 278–
336). Three amino acids located immediately N-terminal to the
FKH domain are important for this inhibition, and their mutation
(D329V, Y330H, and K332L) impaired Treg suppressive function.
Thus, the interaction between AML1 and FOXP3 may be another
potential therapeutic target for controlling Treg activity.
FKH DOMAIN
As a member of Fox family, FOXP3 contains a FKH domain
responsible for DNA binding and consequently for its activa-
tor/repressor functions. More than half of patients with IPEX
syndrome have missense mutations in exons encoding the FKH
domain (70–74). Mutations in the FKH domain of patients with
IPEX have been shown to affect DNA binding (8, 51, 75). FOXP3-
binding to DNA requires multimerization and it has been shown
that FKH domain of FOXP3 forms a domain-swapped dimer,
simultaneously engaging and bringing into close proximity two
distant FOXP3-binding sites in DNA (55). Thus, it seems that both
the DNA-binding FKH domain and an intact LZ domain of FOXP3
are needed for homo-multimerization of FOXP3, DNA bind-
ing, and consequently for FOXP3-mediated suppressor functions
(55, 76).
FOXP3 can regulate gene expression of number of genes that
are also targets for NFAT transcription factor. This activity was jus-
tified by the capacity of FOXP3 to interact physically with NFAT
(60). The mechanism by which FOXP3 influences the expression
of NFAT-dependent genes is under study. It has been suggested
at least three modes of action of FOXP3 to inhibit the expres-
sion of genes regulated by NFAT: (i) by competing with NFAT
for binding to DNA (77–79), (ii) by sequestering NFAT away
from DNA (based on the finding that NFAT and FOXP3 physi-
cally interact in cell lysates (60)) or by sequestering other NFAT
partners, such as AP-1 (52), and (iii) by forming a cooperative
complex (46) (Figure 1). Regarding the third option, Wu and col-
leagues showed that the repressive effect of FOXP3 on cytokine
gene expression and its activating effect on other genes, such as
CTLA4 and CD25, is in fact driven by a cooperative complex
formation between NFAT and FOXP3. NFAT binds cooperatively
with transcription factors of the AP-1 (Fos/Jun) family to com-
posite NFAT:AP-1 sites, found in the regulatory regions of many
genes that are induced during lymphocyte activation (80). But,
depending on its partner, NFAT seems to direct two entirely con-
trary biological programs: (i) T cell activation by recruiting AP-1
to the regulatory regions of appropriate target genes and (ii) T
cell tolerance by recruiting FOXP3 (46). The cooperative complex
FOXP3:NFAT is required to repress expression of the cytokine IL-
2, upregulate expression of the Treg markers CTLA4 and CD25,
and confer suppressor function (46). In a recent paper, Banduk-
wala et al. (55), solved the crystal structure of the FKH domain
of FOXP3 bound to DNA in conjunction with the DNA-binding
domain of its partner, NFAT1. This work showed that a region
of FOXP3 identified as Wing1, and specially aminoacids 399–401
from FOXP3, inserts into the CX-E’F-fg groove of NFAT that con-
tains a string of positively charged residues, K664, R665, K666, and
R667 (55). Mutations that disrupt Foxp3 interaction with NFAT,
interfere with the ability of FOXP3 to repress expression of the
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FIGURE 1 | Mechanism by which FOXP3 influences the expression of NFAT-dependent genes: (i) by competing with NFAT for binding to DNA (77–79)
(ii) by sequestering NFAT away from DNA (60) or by sequestering other NFAT partners, such as AP-1 (52) and (iii) by forming a FOXP3:NFAT
cooperative complex (46).
cytokine IL-2, upregulate expression of the Treg markers CTLA4
and CD25, and the suppressor function (46).
The FKH domain is also implicated in the nuclear localization
of FOXP3. Indeed, it has been demonstrated that a C-terminal
fragment of Foxp3 containing the entire FKH domain with short
flanking sequences at each end was necessary and sufficient for
import of FOXP3 to the nucleus (51). However, nuclear import
of transcription factors are regulated at multiple levels, includ-
ing post-translational modifications, binding and release from
compartment-specific anchors, and the selective utilization of
specific transport factors (81). It is not known whether FOXP3
nuclear translocation can be regulated by other transcription fac-
tors. Indeed, it has been shown that the interaction between Foxp3
and c-Rel may contribute to the nuclear translocation of FOXP3
(60, 61).
Forkhead domain of FOXP3 has been also implicated in the
interaction with the hypoxia-inducible factor 1 (HIF-1α). It has
been described that HIF-1 enhances Th17 development through
direct transcriptional activation of RORγτ and via tertiary com-
plex formation with RORγτ and p300 recruitment to the IL-
17 promoter. HIF-1α attenuates T(reg) development by binding
FOXP3 and targeting it for proteasomal degradation (42). These
findings highlight the importance of metabolic cues in T cell
fate determination and suggest that metabolic modulation could
ameliorate certain T cell-based immune pathologies.
FOXP3 POST-TRANSLATIONAL MODIFICATIONS
Post-translational modifications, including phosphorylation,
acetylation, ubiquitination, sumoylation, methylation, and
hydroxylation, are recognized as important determinants for the
dynamic regulation of transcription factors (82). As mentioned
above, FOXP3 activity can be regulated by acetylation, a process
catalyzed by distinct types of HATs and non-histone proteins that
are activated/inhibited in response to extrinsic cellular signals. It
has been demonstrated that acetylation/deacetylation of FOXP3,
in response to stimuli such as TGF-β or IL-6, affects FOXP3 sta-
bility and its promoter binding activity (83, 84). It is clear that
HAT and HDACs, such as TIP60, p300, HDAC7, HDAC9, or
SIRT1, are components of the Foxp3 interactome and are involved
in regulating the acetylation status of Foxp3 [reviewed in (85)].
FOXP3 acetylation can increase its stability. Indeed, the histone
acetyl transferase p300 competes for lysine residues with E3 ubiq-
uitin ligase, which can target FOXP3 for its degradation (86). As
mentioned above, FOXP3 degradation directed by HIF-1α during
Th17 development (42).
FOXP3 activity can also be regulated by phosphorylation.
The primary structure of FOXP3 contain four cyclin-dependent
kinase (CDK) motifs (Ser/Thr-Pro) located within the N-terminal
domain. It has been shown very recently that cyclin-dependent
kinase 2 (CDK2) together with cyclin E can phophorylate these
sites and regulate Foxp3 stability and affect negatively its suppres-
sor function (87). It has also been demonstrated that phosphoryla-
tion of FOXP3 at serine 418 affects its transcriptional activity and
Treg function (88). The authors showed in rheumatoid arthritis-
derived Treg cells that Ser418 was specifically dephosphorylated
by protein phosphatase 1 (PP1), whose expression and enzymatic
activity ca be induced by tumor necrosis factor α (TNF-α) leading
to impaired Treg-cell function. These data highlight how Treg-cell
function may be subverted by pro-inflammatory cytokines such
as TNF-α in inflammatory diseases, and how it can be reversed by
TNF-α antagonism (88).
FOXP3 AS A TARGET FOR DRUG DEVELOPMENT
FOXP3 is a multifaceted transcription factor with a major role in
the control of immune homeostasis mediated by Treg cells. But
also, FOXP3 expression has been shown to be induced transitorily
on CD4+ T cells upon TCR stimulation leading to hyporespon-
siveness of the cell. This finding suggests that the induction of
FOXP3 serves to shut off T cell activation. It is widely acknowl-
edged that inhibiting Treg-cell function in patients with cancer is
essential to improve the efficacy of anti-tumoral therapies. But, on
the other hand, FOXP3 has emerged as an important regulator of
some oncogenes and as a tumor suppressor factor able to control
cell proliferation of tumor cells. Therefore, how should the func-
tion of Foxp3 be inhibited in Treg cells and effector T cells without
altering the beneficial effects of Foxp3 on tumors?
Several strategies have been proposed to neutralize Treg activ-
ity. Thus, it has been shown that administration of low doses of
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FIGURE 2 | Schematic representation of some of the FOXP3 partners,
their site of interactions and functions. The N-terminal domain of FOXP3
can interact with c-Rel (nuclear factor κB transcription factor c-Rel), RORγt
(Retinoic acid receptor-related orphan receptor gamma t), RORα
(Retinoid-related orphan receptor alpha), Eos (Ikaros family zinc finger 4,
IKZF4), TIP60 (histone acetyltransferase TIP60), HDAC7 (histone deacetylase
7), FIK (FOXP3-interacting KRAB domain containing protein), c-Jun
(transcription factor c-Jun), STAT3 (Signal transducer and activator of
transcription 3), IRF4 (interferon regulatory factor 4). The Leucine zipper
domain can interact with FOXP3, FOXP1, or H1.5 (Histone H1.5). The FKH
domain can interact with FOXP3, NFAT (nuclear factor of activated T cells), the
DNA or HIF-1α (Hypoxia-inducible factor 1α). Dots in red represent sites of
phosphorylation and dots in blue represents sites of acetylation. NLS, nuclear
localization sequences.
cyclophosphamide is able to deplete Treg and favors anti-tumor
therapies (89–91). Also, targeting the alpha-subunit of the IL-2
receptor by using a fusion protein between the IL-2 and the diph-
theria toxin has been tested in clinical trials with different results
(89, 90). However, these strategies lack of high specificity and
might eliminate both effector T cells and Treg cells. In addition,
depletion of Treg cells by these strategies also raises the possibility
of autoimmunity (91). Other approaches have been directed to
inhibit factors produced by Tregs, such us transforming growth
factor-β (TGF-β). We have shown that a peptide inhibitor of
TGF-β inhibited Treg activity and improved protective anti-tumor
immunogenicity elicited by a vaccine (92, 93). These data suggest
that inhibition of TGF-β, in particular by small molecules that
might penetrate the interface between contacting T cells, would
be a valuable tool to inhibit Treg activity and consequently, these
molecules might be useful to potentiate antiviral or anti-tumor
immunotherapies. However, there are other options to regulate
Treg activity by targeting FOXP3 directly. As it has been described
above, FOXP3 orchestrate a transcriptional network in collabora-
tion with a large number of cofactors, and thus, the complexity
of FOXP3 interactome may determine the final outcome of the
cell. In Figure 2 we summarize some of the cofactors identified as
partners of FOXP3 and through which FOXP3 exerts some of its
functions. Regulation of the members of the FOXP3 interactome
may offer opportunities for the development of new treatments
for autoimmune diseases, cancer, or infectious diseases. In a pre-
vious work, using a phage displayed peptide library we identified a
15-mer synthetic peptide, P60, able to enter into the cells, bind to
FOXP3, inhibit FOXP3 nuclear translocation, and reduce its ability
to suppress the transcription factors NF-κB and NFAT impairing
Treg activity in vitro and in vivo (94). The specific region of FOXP3
which interacts with the peptide has not been elucidated yet, but it
is clear that peptide P60 inhibits only certain number of functions
ascribed to FOXP3, without altering others.
There are many opportunities to disrupt specific elements of
FOXP3 interactome which should be investigated. Thus, small
molecules targeting HAT/HDAC or disrupting their interactions
with FOXP3 are interesting candidates for the regulation of Treg
function in vaccines and tumor therapies (85). Similarly, inhi-
bition of FOXP3 interaction with phospsphorylated c-Jun, Eos,
c-Rel, FIK, ROR, AML1, or NFAT might lead to the inhibition
of specific functions of FOXP3. Clearly, small molecules targeting
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these proteins are candidates for the regulation of Treg function in
vaccines and tumor therapies.
Moreover, there are also opportunities to modulate the post-
translational modifications of FOXP3 by regulating the activity
of HAT/HDAC complex (95). Thus, several HDAC inhibitors
have been proved to enhance the production and suppressive
functions of FOXP3(+) regulatory T cells, being effective in
murine models of arthritis, allograft rejection, and colitis (96–
98). Similarly, modification of the phosphorylation status of
FOXP3 may offer opportunities to modulate its activity. Strate-
gies to enhance CDK2 and cyclin E activity might downregu-
late the stability and activity of FOXP3 and control Treg func-
tion (87). However, it must be emphasized that new drugs
to inhibit FOXP3 functions should preserve its antiprolifera-
tive activities which are beneficial for the control of tumor cell
growth.
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